Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01592786 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
A Phase 2 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 906
- Enrollment target
NCT01592786 is a Phase 2 study that has completed, run by Forest Laboratories. The registered enrollment target is 906 participants.
The verdict
NCT01592786, a Phase 2 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 906 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of memantine in pediatric (6-12 years old) patients with autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) and to identify responders for participation in a follow-up randomized withdrawal study.
Interventions
- DRUG Memantine Hydrochloride (HCl)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 906 participants |
| Start Date | 2012-06 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01592786
The ClinicalTrials.gov registry entry for NCT01592786 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 906 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Memantine Hydrochloride (HCl) is the first listed.
NCT01592786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01592786 about?
NCT01592786 is a clinical study titled "An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)". The purpose of this study is to evaluate the safety and tolerability of memantine in pediatric (6-12 years old) patients with autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) and to identify responders for participation in a follow-up randomized with...
What is the current status of trial NCT01592786?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 906 participants. The study started on 2012-06. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01592786?
The interventions under investigation include: Memantine Hydrochloride (HCl) (DRUG).
Who is sponsoring clinical trial NCT01592786?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.